



ISSN: 2250 – 2688

Received: 28/02/2022

Revised: 20/03/2022

Accepted: 25/03/2022

Published: 06/04/2022

**Yash Anand Sinha Rohit Kumar  
Bijauliya, Sunny Patel and Danishta  
Asif**

*Bareilly International University  
Bareilly-243006, Uttar Pradesh India*

#### Correspondence

**Yash Anand Sinha**

*Research Scholar, BIU College of  
Pharmacy, Bareilly International  
University, Bareilly-243006, Uttar  
Pradesh India*

**Email:** [rkpharma3791@gmail.com](mailto:rkpharma3791@gmail.com)

**DOI:** 10.24092/CRPS.2022.120102

**Website:** [www.crpsonline.com](http://www.crpsonline.com)

**Quick Response Code:**



## A Comparative Review on Epilepsy and its Treatment Options

**Yash Anand Sinha, Rohit Kumar Bijauliya, Sunny Patel and Danishta Asif**

### ABSTRACT

In today's fast-paced society, individuals are subjected to numerous forms of stress, and the majority of the world's population suffers from various neurological disorders. The imbalance of excitatory and inhibitory neurotransmitters is one of the mechanisms driving epilepsy. Epileptic seizures can cause loss of awareness, tremors, disorientation, difficulties reacting, and visual or other sensory symptoms, depending on which parts of the brain are implicated. The usage of benzodiazepines, barbiturates, and ion channel modulators in the treatment of epilepsy was categorised depending on the place of origin and symptoms. Allopathic treatment should typically begin with a single antiepileptic medication. Ayurvedic treatment approaches include purifying measures such as therapeutic purgatives and pacifying therapies such as single herb and polyherbal formulations. The review's goal is to look at pathogenesis, epilepsy categorization, signs and symptoms, allopathic and Ayurvedic medicine therapy, and future trends in epilepsy.

**Key words:** Epilepsy, Seizures, Allopathic treatment, Ayurvedic.

### 1. INTRODUCTION

Epilepsy comes from the Greek word epilambanein, which means "to assault" or "to seize." Epileptics were supposed to be visited by demons or gods in the past. Hippocrates, a Greek physician who lived around 400 B.C., believed that epilepsy was a brain ailment, and he was correct.<sup>1</sup> Epilepsy is a persistent neurological condition that can cause long-term alterations in the brain circuitry, even if it occurs only occasionally. Comorbidities, such as mental and cognitive deficits, are common in this disease.<sup>2</sup> Epilepsy affects up to 1% of the population, making it the most frequent neurological disorder after stroke.<sup>3</sup> Epilepsy affects around 50 million individuals globally, with 90% of them living in underdeveloped nations.<sup>4</sup> In recent years, the public's opinion of epilepsy has improved in various ways. It is a common chronic neurological illness characterized by recurring unprovoked epileptic seizures as the balance between brain excitability and inhibition shifts toward uncontrolled excitability.<sup>5, 6, 7</sup>

Seizures come in a variety of forms, each with distinct behavioural and electrophysiological manifestations that can generally be identified in scalp electroencephalographic (EEG) recordings.<sup>8</sup> A seizure is a brief epileptic episode that occurs when brain activity is disrupted. A single seizure may not always indicate that someone has epilepsy.<sup>8, 9</sup> 10% of individuals will have a seizure at some point in their lives.

The duration of a seizure might range from a few seconds to many minutes. Convulsions, loss of consciousness, blank gazing, lip smacking, and jerking motions of the arms and legs are only some of the signs and symptoms that patients and health care workers may not identify.<sup>10</sup> The onset, middle, and end of a seizure are all distinct.

## 2. PHASES OF SEIZURES

Four phases of a seizure can be distinguished.

a) Prodromal phase: This phase begins a few hours or even days before the seizure itself and should not be confused with the aura. Headache, sleeplessness, irritability, sadness, poor temper, or increased activity are all signs of the prodromal phase.

b) Aura: By seconds or minutes, this period precedes the seizure. The seizure episode is just getting started. Extreme terror, odd epigastric sensations, hallucinatory experiences, foul odours, and other sensations are all examples of aura emotions. The aura phase is vivid in the patient's mind.

c) Seizure (ictus phase): There is a loss of consciousness in practically all seizures, and the patient may be unable to provide any information regarding the ictus.

d) Post-ictal phase: This phase may or may not exist, or it may extend for several hours, or even days. Deep sleep and waking up with weariness, headaches, muscle pains, bewilderment, irritability, or ataxia are some of the symptoms. Transient paralysis can last anywhere from a few hours to days.<sup>11</sup>

### 2.1 Classification

There are three main types of seizures: partial, generalized, and unclassified.<sup>9</sup>

#### 2.1.1 Partial Seizures (seizures begin locally)

A. Simple (without impairment of consciousness) with motor symptoms

- with psychic symptoms
- with psychic symptoms.

B. Complex (with impairment of consciousness)

- Impaired consciousness at onset with or without automatisms
- Simple partial onset followed by impairment of consciousness with or without

C. Secondarily Generalized (partial onset evolving to generalized tonic clonic seizures)

#### 2.1.2 Generalized seizures (bilaterally symmetrical and without local onset)

#### 2.1.3 Unclassified Seizures

#### 2.1.4 Status epileptics

## 3. PATHOPHYSIOLOGY

The cerebral cortex manifests itself in paroxysmal seizures. When the excitatory and inhibitory forces within the population of cortical neurons become suddenly imbalanced, a seizure results. A volatile cell membrane or its surrounding/adjacent supporting cells are used to identify the fundamental physiology of a seizure event. The seizure starts in any cortical or subcortical location with a grey count. To begin with, certain neurons fire improperly in a tiny number of cases. Normal membrane conductance, inhibitory synaptic contemporary breakdown, and excess excitability might manifest locally, resulting in a focal seizure, or more widely, resulting in a generalised seizure. This onset spreads via physiologic pathways to encompass places in close proximity to far-flung locations.

A change in potassium conductance, a disease of the voltage-gated ion channels, or a lack of membrane ATPases involved in ion transport can all cause neuronal membrane to become volatile and cause a seizure. Certain neurotransmitters (e.g., histamine, peptides, acetyl choline, glutamate aspartate, cytokines, corticotropin freeing factor, norepinephrine, purines, and steroid hormones) increase neuronal excitability and propagation, whereas GABA and dopamine decrease neuronal excitation and propagation.

The need for blood float to the mind increases during a seizure to take off CO and to provide substrate for metabolic interest of the two neurons. As the seizure progresses, the mind experiences more ischemia, which can lead to neuronal loss and mental damage.<sup>[12]</sup>

Some types of epilepsy are linked to mutations in a number of genes. The generalised epilepsy and infantile seizures disorders have been linked to genes that code for protein subunits of ligand-activated ion channels and voltage sensitive.<sup>[13]</sup> Seizure awareness is located inside the temporal lobe in psychomotor epilepsy.<sup>14</sup>

### 3.1 Signs and Symptoms of Epilepsy<sup>15</sup>

#### 3.1.1 Generalised

- All parts of brain affected
- Tonic: clonic Motor, consciousness Tonic and clonic convulsions, loss of consciousness

- Myoclonic: Motor Jerking limbs

### 3.1.2 Partial

- Frontal lobe Motor Twitching, jerking
- Temporal lobe Sensory Smells, epigastric sensation & any other sensations.
- Behaviour Psychiatric
- Parietal lobe Sensory Tingling etc.

## 3.2 Management and Treatment

### 3.2.1 Management of Epilepsy by Allopathic medicine:

The phrases anticonvulsant and antiepileptic are interchangeable. Anticonvulsants inhibit artificially caused seizures in laboratory animals, whereas anti-epileptic drugs are used to treat epilepsies in humans.<sup>[16]</sup>

#### 3.2.1.1 Principles of management:

- Patients should be informed about the condition, the length of therapy, and the need of adherence.
- Any factor that causes epilepsy, such as a brain tumour, should be addressed.
- Expect natural variation; for example, attacks may occur more frequently or solely around menstruation in women.
- Avoid inciting conditions like alcohol and sleep deprivation while precipitating. stress on the mind
- Only use the antiepileptic if the kind of seizure and frequency warrant it, which means more than one modification every 6-12 months.<sup>17</sup>

#### 3.2.2 Allopathic treatment of epilepsy

A single anti-epileptic drug should be used to begin treatment (AED). Until seizure control is obtained, the dosage should be progressively raised. If the first therapy is unsuccessful, a second AED can be used. The second drug's dose is gradually raised until the maximum tolerable dose is reached. If the first medicine is unsuccessful, the second drug is progressively withdrawn, and then combination therapy is tried. "Conventional" or "first-line" medicines include phenytoin, phenobarbitone, carbamazepine, oxcarbazepine, and valproate. Other AEDs, such as vigabatrin, topiramate, and zonisamide, are referred to as "second-line" or "new" medicines. It is advisable to start with a traditional AED because they are less costly and have less adverse effects. When the first line medicines are contraindicated, newer AEDs can be administered instead.<sup>15</sup>

#### 3.2.3 Management of epilepsy by Ayurvedic drug

Apasmara is a type of disease that affects both the mind and the body. The aetiology of Apasmara is described as eating unwholesome and unclean food, engaging in harmful behaviours, suppressing mental attributes reflecting purity, and disrupted Dosha (humour) balance all have a part in the manifestation of the disease.<sup>21</sup> It is categorised as Vattaja, Pittaja, Kaphaja, and Sannipataja based on the prominent Dosha (humour) involved in its pathophysiology and clinical presentation of epilepsy. These techniques might be regarded palliative and curative in nature, bringing the body back to a physiological state from a diseased one.

## 4. CONCLUSION

Epilepsy is a neurological disorder that mostly affects the central nervous system. It has an impact on one's physical, psychological, family, and professional lives. As a result, anticonvulsant medication is chosen largely for its efficacy in treating certain types of epileptic seizures and epilepsy. Despite early and appropriate daily therapy with a sufficient anticonvulsant medication, a significant number of individuals with epilepsy suffer from intractable or drug-resistant epilepsy. Excessive firing of excitatory neurotransmitters and a reduction in inhibitory neurotransmitter activity characterize epilepsy. Epilepsy is best treated with benzodiazepines, barbiturates, and ion channel modulators. If seizures are not controlled with monotherapy, polytherapy is a recommended treatment for epilepsy in Ayurveda, which includes pharmacological and non-pharmacological measures with many herbal, herbo-mineral formulations in different dosage forms with a variety of techniques to provide good control of seizures for most people with epilepsy.

## 5. ACKNOWLEDGEMENT

The authors are thankful to Mr. Rohit Kumar Bijauliya, Assistant Professor, BIU College of Pharmacy, Bareilly International University, Bareilly for his guidance to carry out this research work successfully.

## REFERENCES

1. National Institute of Neurological Disorders and Stroke. Seizures and epilepsy: Hope through research. Available at: [www.ninds.nih.gov/disorders/epilepsy/detail\\_epilepsy.htm](http://www.ninds.nih.gov/disorders/epilepsy/detail_epilepsy.htm). Accessed January 19, 2010.
2. Rudzinski LA, Meador KJ. Epilepsy and neuropsychological comorbidities. *Continuum (Minneapolis)* 2013;19: 682–96.
3. Carl E S. Epilepsy: a review of selected clinical syndromes and advances in basic science. *Journal of Cerebral Blood Flow & Metabolism* 2006; 26:983-04

**Table 1: Mechanism of Anti-epileptic drugs** <sup>18, 19, 20</sup>

| S. No. | Drug             | Mechanism of action  |
|--------|------------------|--|
| 1      | Carbamazepine    | Suppress seizure spread. Inhibit voltage gated sodium channel.   |
| 2      | Clobazam         | Binds and activates GABAA receptor which increase the frequency of Cl-channel opening.   |
| 3      | Diazepam         | Binds and activates GABAA receptor, which increase the frequency of Cl-channel opening.  |
| 4      | Ethosuximide     | Inhibition of T-type calcium channels.   |
| 5      | Felbamate        | Increases intracellular Ca <sup>2+</sup> and blocks excitatory postsynaptic potentials.  |
| 6      | Gabapentin       | Enhances GABA release.   |
|        | Lamotrigine      | Blocks sodium channels. Presynaptically, it inhibits the release of excitatory amino acids. Postsynoptically, it diminishes the excitability of neurons. |
| 7      | Levetiracetam    | Enhances the release of inhibitory neurotransmitter.   |
| 8      | Oxcarbazepine    | Inhibits voltage-dependent fast sodium channels. Hyponatremia, sedation, dizziness.  |
| 9      | Phenytoin        | Enhances the release of inhibitory neurotransmitter.   |
| 10     | phenobarbital    | Binds and activates GABAA receptor which increase the frequency of Cl-channel opening.   |
| 11     | Sodium valproate | Prolongation of Na <sup>+</sup> channel inactivation and augments release of GABA.   |
| 12     | Tiagabine        | Inhibits GABA uptake.  |
| 13     | Topiramate       | Potentialiation of GABAA receptor-mediated currents.   |
| 14     | Vigabatrin       | Inhibits GABA-transaminase and increase synaptic GABA concentration.   |
| 15     | Zonisamide       | Blockade of sodium channels, reduction of voltage dependent calcium currents and glutamate induced synaptic excitation.                                  |

**Table 2: Herbs having anticonvulsant activity for the management of Epilepsy described in Ayurveda [22, 23]**

| Common Name | Plant Name                               | Active Principle  | Mechanism of Action and activity   |
|-------------|--|---|--|
| Clove       | <i>Eugenia caryophyllus</i><br>Myrtaceae | Eugenol, acetyleugenol, $\beta$ -caryophyllene, vanillin, crategolicaci, tannins, gallotanic acid methylsalicylate, flavonoids, eugenin, kaempferol, rhamnetil, eugenitin & triterpenoidslike oleanolic acid. | Increases onset of convulsions.<br>Reduce duration of convulsions.<br>Delay onset on seizures.<br>Increase GABAergic and glycinergic activity. |
| Coconut     | <i>Cocos nucifera</i><br>Arecaceae       | Monounsaturated fatty acids, Saponins.  | Inhibit PTZ induced convulsions. Increase GABA level, serotonin level.   |
| Karkandu    | <i>Zizphus jujube</i><br>Rhamnaceae      | Flavonoids, saponins, tannins, vitamin A, vitamin B, sugars, mucilage, calcium, phosphate & iron.   | Anticonvulsant action  |
| Lotus       | <i>Nelumbo nucifera</i><br>Nelumbonaceae | N-nornuciferine, O-nornuciferine, nuciferine, and roemerine, protein, amino acids, unsaturated fatty acids, minerals, starch, and tannins.  | Decrease tonic extensor convulsions.<br>Anticonvulsant action  |
| Mango       | <i>Mangifera indica</i><br>Anacardiaceae | Polyphenolics, triterpenoids, mangierin, catechin, iso-mangiferin, alanine, glycine, $\gamma$ -aminobutyric acid, kinic acid  | Inhibit PTZ and MES induced convulsions, increases GABA levels, Anticonvulsant action.   |

|           |   |   |  |
|-----------|---|---|--|
| Musta     | <i>Cyperus rotundus</i><br>Cyperaceae           | Cyperone, selinene, cyperene, cyperotundone, patchulenone, sugeonol, kobusone and isokobusone, pinene (monoterpene) derivatives of sesquiterpenes such as cyperol, isocyperol and cyperone. | Anticonvulsant action.   |
| Nagkesara | <i>Mesua ferra</i><br>Calophyllaceae            | Sesquiterpene, diterpenes, triterpenes, carboxylic acids and saturated hydrocarbons   | Reduce HLTE. Inhibit MES induced convulsions. Increases the onset time of seizures and decreases the duration of seizure.  |
| Nutmeg    | <i>Myristica fragrans</i><br>Myristicaceae      | Myristicin and Macelignan   | Inhibit seizures and uses the severity of seizures.  |
| Saffron   | <i>Crocus sativus</i><br>Iridaceae              | Crocetin, picrocrocin, safranal, isophorone   | Increases seizure threshold, block PTZ induced convulsions, increases GABA-ergic neurotransmission, Inhibit absence seizure, Improve tonic clonic seizures.  |
| Spikenard | <i>Nardostachys jatamansi</i><br>Caprifoliaceae | Valeranone, Calerene, patchouol, $\alpha$ -gurjunene, aristolone, $\beta$ -maalien, spathulenol   | Increases seizure threshold, inhibit the electroshock convulsions Increases GABA, 5-HT, 5-HIAA.  |
| Sesame    | <i>Sesamum indicum</i><br>Pedaliaceae           | Propanone, ethanone   | Decrease ROS, MDA in epileptics  |
| Sway      | <i>Acorus tatarinowii</i> Schott<br>Acoraceae   | Essential oils and asarone  | Prevents convulsion related GABA -ergic neuron damage in the brain, Neuro protective against N-methyl-D-aspartate or Glu-induced excitotoxic neuronal cell, Recepting-binding assay act as specific binding to striatal dopamine D1 and D2 receptors |
| Tagara    | <i>Valeriana wallichii</i><br>Caprifoliaceae    | Valerian, valipotriates GABA sesquiterpene, diterpenes, triterpenes, carboxylic acids and saturated hydrocarbons  | Sedative action.<br>Decrease HLTE.<br>Anticonvulsant activity.   |

**Table 3: Ayurvedic Formulations used for the management of Epilepsy [24-31]**

| S. No. | Formulation   | Name of formulation | Mechanism of action and activity            |
|--------|---------------|---------------------|---|
| 1      | Arka          | Rasonadi Arka.      | As adjuvant drug                            |
| 2      | Aasava-Arista | Aswagandharista     | Antipsychotic drug Especially for epilepsy. |
|        |               | Saraswatarista      | Intellect promoting & Antipsychotic drug.   |
| 3      | Avaleha       | Chandravaleha       | Epileptic effect                            |
| 4      | Churna        | Saraswata           | Nootropic and cognition enhancer.           |
|        |               | Jatamansi           | Sedative and anxiolytic effect.             |
|        |               | Aswagandha          | -   |

|   |            |                     |   |
|---|------------|---------------------|---|
|   |            | Sarpagandha         | Used in hysterical fits, insomnia   |
| 5 | Ghrita     | Panchagavya         | Controls the frequency of convulsions and Duration of convulsions. It can be given for a long duration of time in therapeutic dosage without the fear of any side-effects.  |
|   |            | Kushmanda           | Increases memory and reduces stress.  |
|   |            | Brahmi              | Reduces the extensor tonus phase of convulsion in their standard doses, as a Shamana Sneha provided significant relief in severity, frequency of attack, salivation, pre and post ictal features in comparison to other groups. Brahmi Ghrita in the form of Brumhana Sneha shown better relief in duration of attack and impaired higher mental functions. |
|   |            | Mahapancha gavya    | Especially for epilepsy and it controls the frequency of convulsions. Mahachaitasa Contents are Jeevaniya Dravyas which plays Rasayana effect on body and also effective for cognitive development of patient. Specially for insanity & epilepsy.   |
| 6 | Kwatha     | Manasyadi           | Used in hysterical fits.  |
|   |            | Dasamula Kashaya    | Used as anupana in Apasmara along with Kalyanaka Ghrita.  |
| 7 | Rasausadhi | Chaturbhujara       | Anticonvulsant effect.  |
|   |            | Smritisagara rasa   | Intellect promoting, reduces the stress.  |
|   |            | Unmada Gajakesari   | Antiepileptic activity after prolonged administration and also balances the excitatory and inhibitory neurotransmitters in CNS, the main action being GABAergic action and additional antioxidant activity of herbs.  |
|   |            | Tantupashana        | Tantupashana is affective against MES seizures in animals and it may be useful in generalized tonic clonic seizures/grandma epilepsy in human beings.   |
|   |            | Kausheyashma Bhasma | Useful in Epilepsy.   |
|   |            | Apasmarara rasa     | Act as an anti-convulsant drug, on MES animal model of convulsion preceded by LD 50 determination. It also has some significant result when compared to other drugs like Phenytoin and Samritisagara rasa.  |
| 8 | Taila      | Bala Taila          | For external application, Apasmaram pranashayet   |
|   |            | Shatavari           | It predominantly Vata Shamaka, have Anulomana (carminative) property. The drug as a whole is Medhya & Rasayana. Considering all these properties, the drug acts on the mind and exhibits anticonvulsive activities.   |
|   |            | Shirisha            | Apasmaramhanyat.  |

4. Epilepsy: aetiology (Sic), epidemiology and prognosis, World Health organization. 2001; Achieved form the original on 2007-05-18. Available at: <http://web.archive.org/web/20070518073641/http://www.who.int/mediacentre/factsheets/fs165/en/Retrieved> 2007-06-14.

5. Commission on Epidemiology and prognosis. International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. *Epilepsia* 1993;34(4):592-96.

6. Blume W, Luders H, Mizrahi E, Tassinari C, Van Emde Boas W, Engel J. Glossary of descriptive terminology for ictal semiology; report of the

- ILAE taskforce on classification and terminology. *Epilepsia* 2001; 42(9):1212-18.
7. Gregory L H, Yehezkiel Ben-A. The Neurobiology and Consequences of Epilepsy in the Developing Brain. *Pediatric Research*2001; 49(3):320-25.
  8. Bazil CW, Morrell MJ, Pedley TA. Epilepsy. In: Rowland LP, ed. *Merritt's Neurology*, 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:990–1008.
  9. Lowenstein DH. Seizures and epilepsy. In: Fauci AS, Kasper DL, Longo DL, eds. *Harrison's Principles of Internal Medicine*, 17th ed. Section 2: Diseases of the Central Nervous System. New York: McGraw-Hill; 2008:2498–2512.
  10. Epilepsy Foundation. About epilepsy and seizures. Available at: [www.epilepsyfoundation.org/about/statistics.cfm](http://www.epilepsyfoundation.org/about/statistics.cfm). Accessed January 10, 2010.
  11. P.A. Dekker, *Epilepsy: A manual for medical and clinical officers in Africa*, 2002.
  12. Sridharan R. Epidemiology of epilepsy. *Current Science* 2002;82 (6):664-70.
  13. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. *Journal of Clinical Investigation* 2005;115(8):2010-17
  14. Porter RJ, Meldrum BS. Antiseizure drugs. In: Katzung BG, ed. *Basic and clinical pharmacology*. New York: Mc Graw-Hill Companies Inc, 10th edition. 2006: 378.
  15. Russell J Greene Norman D Harris, *Pathology and therapeutics for pharmacy*, third edition.
  16. Block JH, Beale JM. *Wilson and Gisvold's text book of organic medicinal and pharmaceutical chemistry*. 11th ed. Lippincott Williams and Wilkins, 2010:503.
  17. Bennett PN, Brown MJ. *Clinical pharmacology*. New Delhi: Elsevier a division of Reed Elsevier India (P) Ltd, 9th ed. 2006: 413-22.
  18. Joseph T. Dipiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey, *Pharmacotherapy A pathophysiologic approach*, seventh edition.
  19. Deshmukh R, Thakur AS and Dewangan D. Mechanism of action of anticonvulsant drugs: a review, *international journal of pharmaceutical research* 2017.
  20. J.W. Sander, Overview of established antiepileptic drugs, chapter 28.
  21. S.Byadagi paramesh warappa, Pandey ajay Kumar: *Textbook of Kayachikitsa, Manasa roga prakarana:vishesha*. Vol 111,1 sted. Chaukambha sanskrit sansthana;2014:447.
  22. Singh Karam, Verma Bhavna: An Ayurvedic insight towards epilepsy. *International journal of research in Ayurveda*. 2012;3(5):682-689
  23. Bansal P, Kaur R, Gupta V, Kumar S.: Is There Any Scientific Basis of Hawan to be used in Epilepsy-Prevention/Cure? *Journal of Epilepsy Research*, 2015;5:33-45.
  24. Pathak Rajneesh, Sharma Arti Patel, Dhananjay: Epilepsy (apasmara) & role of ayurveda in its management. *International Journal of Applied Ayurved Research*. 2016; 2 (5); 562-567.
  25. Rout OM, Acharya R, Gupta R, et al: Management of psychosomatic disorders through ayurvedic drugs- a critical review. *World journal of pharmacy and pharmaceutical sciences* Volume 2, Issue 6, 6507-6537.
  26. Chitrangana CN, Suhas K Shetty, Narayan Prakash B, Arun Raj GR, Vinay Shankar: explorative study on efficacy of ayurvedic therapy and an ayurvedic compound preparation in the management of epilepsy. *International journal of research in ayurveda and pharmacy* 2014; 5(6):702-707.
  27. Joseph R, Vijayapandit, Wele A, Deshmane G. Antiepileptic activity of Unmadagajakesari-A herbomineral formulation. An experimental evaluation. *International journal of phytomedicine*. 2015; 7:106-111.
  28. Pemminati Sudhakar et al; Research article-effect of tantupashan on electrical and chemical induced seizures in mice. *Journal Of pharmacy research* 2010;3(5):1178-1180.
  29. Dole A Vilas, Paranjpe Prakash, *A Text Book of Rasashastra*, 1st ed., Chaukhamba Surbharati Prakashan, Varanasi; 2004. p.383.
  30. Vikas Saroch, Hiremath RS, Patil PA. Anticonvulsant Activity of Apasmara rasa – An Experimental Study. *International Journal of Ayurvedic Medicine*. 2012; 3(1): 48-52.
  31. Chaithra GG et al. Recent updates on management of epilepsy through Ayurveda: A review. *J Pharm Sci Innov*. 2018;7(5):200-207.